Aro Biotherapeutics
PrivateLast Round
Series B
Nov 28, 2023
Total Funding Raised
$142.5M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Aro Biotherapeutics is a biotechnology company that develops tissue-targeted genetic medicines using a proprietary protein platform called Centyrins.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Aro Biotherapeutics Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Aro Biotherapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Nov 28, 2023 | ||||
| Series A | Jan 5, 2021 | ||||
| Seed | Dec 11, 2018 |
Key People
Founding team and executive leadership
Aro Biotherapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| BioMotiv | Seed, Series A |
| Cowen Private Investments | Series A, Series B |
| Ridgeback Capital | Series A |
| TD Securities | Series A, Series B |
| Blue Owl Capital | Series A, Series B |
| Northpond Ventures | Series B, Series A |
| HealthCap | Series A, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 19, 2026
ABX1100, a targeted genetic therapy, is advancing in the rare disease pipeline.
- Jan 7, 2025
Glenn Crater, MD, appointed as new Chief Medical Officer.
Aro Biotherapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Aro Biotherapeutics's valuation, stock price, and market status.